American Radium Society Scientific Papers and Posters 2015

Integrating High-Tech With High-Touch in Radiation Oncology

Program Abstracts From the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Scientific Papers

SCIENTIFIC PAPERS

S001–S010S011–S020S021–S030S031–S040S041–S054

SCIENTIFIC POSTERS

*Scientific posters P001 through P014 have been designated by the American Radium Society as Posters of Distinction.

P001–P010P011–P020P021–P030P031–P040P041–P050P051–P060P061–P070P071–P080P081–P090P091–P100P101–P110P111–P120P121–P130P131–P144

(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience

(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer

(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy

(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis

(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution

(S006) Impact of Delays to Adjuvant Radiation Therapy on Survival in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx

(S007) Intensity of Follow-Up After Radiotherapy for HPV-Positive Oropharyngeal Cancer

(S008) The Impact of HPV, HIV, and Smoking on Oncologic and Functional Outcomes in Patients With Head and Neck Cancer

(S009) Radiation Therapy Improves Outcomes With Desmoplastic Melanoma of the Head and Neck

(S010) A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial-Feasibility and Acute Toxicity

(S011) Hypofractionated vs Standard Fractionated Proton Beam Therapy for Early-Stage Prostate Cancer: Interim Results of a Randomized Prospective Trial

(S012) Trends in the Selection of Definitive Treatment for Newly Diagnosed Prostate Cancer in Men < 60 Years Old

(S013) Heterogeneity Within the Prostate and Risk-Adapting Dose-Volume Analysis With SBRT for Prostate Cancer

(S014) pN+ Prostate Cancer (CaP) Does Not Imply Incurable Disease

(S015) Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States

(S016) Intermediate-Risk Prostate Cancer: A Medicare-Based Cost Comparison of Five Radiotherapy Regimens

(S017) Factors Associated With Regional Recurrence Following Lymphadenectomy for Penile Squamous Cell Carcinoma

(S018) Intensity-Modulated Radiation Therapy or Conformal Radiation Therapy and Cardiopulmonary Mortality Risk in the Elderly With Esophageal Cancer

(S019) Radiation-Induced Liver Disease Following Liver SBRT for Primary Hepatic Malignancies: Analysis of a Prospective Institutional Study

(S020) Predictors of Local-Regional Failure and the Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer

(S021) The Role of Neoadjuvant Stereotactic Body Radiation Therapy in Pancreatic Cancer

(S022) Experimental Insight Into the Preferential Cytotoxicity of Cancerous vs Noncancerous Cells of Metformin

(S023) Ultrasound Tissue Characterization of Breast Fibrosis Following Hypofractionated Breast Radiotherapy

(S024) Impact of Pelvic Radiotherapy on Sexuality Reported by Women Surviving Cancer

(S025) Discovery and Validation of Predictive Factors for Safety Incident Reports in Patients Receiving Radiation Therapy: Comparative Results From a Large Safety Variance Database

(S026) A Novel Method for Detecting Serious Cardiac Device Errors in Patients Receiving Radiotherapy Using Daily Pulse Checks

(S027) Novel Mechanisms of Adaptive Resistance in Head and Neck Cancer

(S028) Patient-Level DNA Damage and Repair Pathway Profiles Are Prognostic After Prostatectomy for High-Risk Prostate Cancer

(S029) Evaluating the Role of a 21-Gene Expression Assay in Directing Adjuvant Radiotherapy Decisions for Elderly Women With Early-Stage Breast Cancer

(S030) Breast Conservation in Young Women in the Modern Era

(S031) Dosimetric Analysis of Left-Sided Breast Cancer Treatment With Tomotherapy IMRT, IMRT, VMAT, and 3D-CRT

(S032) Complications of Contralateral Prophylactic Mastectomy With Tissue Expander Reconstruction and Potential Impact on Adjuvant Oncologic Therapy

(S033) Predictive Capacity of Three Comorbidity Indices in Estimating Survival Endpoints in Women With Early-Stage Endometrial Carcinoma

(S034) Pilot Phase II Trial of "Sandwich" Radiation and Combination Carboplatin and Paclitaxel Chemotherapy in Patients With High-Risk Endometrial Cancer

(S035) Cervical Cancer Outcome Prediction to High-Dose-Rate Brachytherapy Using Quantitative Magnetic Resonance Imaging Analysis of Tumor Response to External Beam Radiotherapy

(S036) Circulating Tumor DNA and Implications for Clinical Decision-Making in Stage I NSCLC

(S037) Phenotypic Diversity Measured in PET/CT Scans Predicts Overall Survival in Early-Stage Lung Adenocarcinoma

(S038) Pulmonary Dose-Volume Predictors of Radiation Pneumonitis Following Stereotactic Body Radiation Therapy

(S039) High-Resolution 4D Ventilation and Perfusion PET/CT Facilitates Functionally Adapted Intensity-Modulated Radiation Therapy (IMRT) in Lung Cancer

(S040) Has Severe Acute Esophagitis Been Reduced by 21st Century Treatment Modalities Among Patients With Limited-Stage Small-Cell Lung Cancer?

(S041) The Role of Chemoradiation in Elderly Limited-Stage Small-Cell Lung Cancer Patients

(S042) Factors Influencing Brain Recurrence After PCI Among Patients With Limited Small-Cell Lung Cancer

(S043) Changes in Quality of Life After Radiation Therapy for Localized Prostate Cancer After Dissemination of Intensity-Modulated Radiation Therapy

(S044) Patient-Reported Quality of Life After Stereotactic Body Radiotherapy (SBRT), Intensity-Modulated Radiotherapy (IMRT), and Brachytherapy

(S045) Equivalent Survival With Breast-Conserving Therapy and Mastectomy in Young Women Under the Age of 40 With Early-Stage Breast Cancer: A National Registry-Based Stage-by-Stage Comparison

(S046) Prognosis for Patients With Metastatic Breast Cancer Who Achieve ‘No-Evidence-of-Disease’ Status After Systemic or Local Therapy

(S047) Radiotherapy vs Chemotherapy Effects on Neuronal Architecture and Spine Density in the Hippocampus

(S048) Identification of Excellent and Poor Prognostic Groups After Stereotactic Radiosurgery for Spinal Metastasis: Secondary Analyses of Mature Prospective Trials

(S049) Salvage Stereotactic Radiosurgery for Locally Recurrent Brain Metastases Treated Previously With Stereotactic Radiosurgery

(S050) Cost-Effectiveness of Neurocognitive Preservation for Whole-Brain Radiotherapy

(S051) The Role of Temozolomide in the Treatment of Low-Grade Glioma

(S052) Inverse Optimization for Correlating 4DCT Ventilation Imaging and Radiation Dose

(S053) Nodal Surveillance With Diffusion-Weighted MRI After Definitive (Chemo) Radiotherapy for HPV-Predominant Squamous Cell Cancers of the Oropharynx and Unknown Primary

(S054) Long-Term Survival and Racial Differences in Pediatric Hodgkin Lymphoma Patients From the State of Florida: Three Decades of Experience

Scientific Posters

*Scientific posters P001 through P014 have been designated by the American Radium Society as Posters of Distinction.

(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status

(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk

(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer

(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy

(P006) The Role of Sequential Imaging in Cervical Cancer Management

(P007) Pooled Analysis of Locoregional Relapse After Minimally Invasive Surgery Alone for Intermediate- or High-Risk HPV+ Oropharyngeal Squamous Cell Carcinoma

(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)

(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery

(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure

(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis

(P012) Characteristics of Mentorship During Radiation Oncology Residency

(P013) Perioperative Mortality in Nonelderly Adult Patients With Cancer: A Population-Based Study Evaluating Healthcare Disparities in the United States According to Insurance Status

(P014) Absence of Infection From Injection of a Rectal Spacer Into the Anterior Perirectal Fat Space

(P015) Radiation Biological Responses of MRI-Linac vs Linac in Human Head and Neck and Lung Cancer Cells

(P016) The Cell Cycle Inhibitor P21 Regulates Langerhans Cell Radiation Resistance and Promotes T Regulatory Cell Induction Upon Exposure to Radiotherapy

(P017) Dosimetric Evaluation of Respiratory-Gated Radiotherapy for Left-Sided Breast Cancer

(P018) Accelerated Partial Breast Radiotherapy Using VMAT-A Preliminary Dosimetric Comparison to Single-Entry Brachytherapy

(P019) Predictors of Outcomes in Breast Cancer Patients With Oligometastases

(P020) 3D Conformal External Beam Radiation Therapy May Result in Lower Heart Dose and Risk of Radiation-Induced Major Coronary Events Compared With Multicatheter Balloon High-Dose-Rate Brachytherapy for Left-Sided Breast Cancer Patients

(P021) Improving Clinical Documentation and Prospectively Populating a Research Database Through an Electronic Data Capture System for Routine Clinical Care

(P022) Proton Therapy on an Incline Beam Line: Acute Toxicity Outcomes in Locally Advanced Breast Cancer Patients

(P023) Dosimetric Evaluation of Accelerated Partial Breast Irradiation Utilizing the ViewRay Magnetic Resonance Image-Guided Radiation Therapy System

(P024) Predictors of Radiation-Induced Skin Toxicity: Data From a Prospective Cohort Receiving Breast Radiation

(P025) T3 Tumors and Breast Conservation

(P026) Is Cause-Specific Survival Similar for Estrogen Receptor- and Progesterone Receptor-Negative Early-Stage Invasive Lobular and Invasive Ductal Cancers? A National Registry SEER Database Study

(P027) Increasing Use of Postlumpectomy Radiotherapy for Ductal Carcinoma In Situ of the Breast in the United States

(P028) Adjuvant Radiation Therapy After Lumpectomy According to Insurance Status

(P029) A Comparison of CT- and MRI-Defined Lumpectomy Cavity for Radiotherapy Planning of Breast Cancer

(P030) Metaplastic Breast Carcinoma at a Single Institution: Clinical-Pathologic Characteristics and Outcome

(P031) Effects of Oncoplastic Surgery on Delivery of Standard Adjuvant Radiotherapy

(P032) Current Management of Low-Grade Central Nervous System Glioma

(P033) MRI Resection Cavity Dynamics Following Brain Metastasis Resection and Permanent Iodine-125 Brachytherapy

(P034) Proton Therapy (PT) Large-Volume Re-Irradiation for Recurrent Glioma: Overall Survival (OS) and Toxicity Outcomes

(P035) Prognostic Factors of Early Deaths in Patients With Craniopharyngioma From the SEER Registry

(P036) Patterns of Care and Outcomes of Adjuvant Radiotherapy for Meningiomas: A Surveillance, Epidemiology, and End Results and Medicare-Linked Analysis

(P037) Analysis of Survival Outcomes in Patients With Multifocal Glioblastoma

(P038) Leukoencephalopathy Following Stereotactic Radiosurgery for Brain Metastases

(P039) Outcomes of Patients With Glioblastoma Receiving Concurrent Radiation Treatment and Antiepileptic Agents With Histone Deacetylase Inhibitor Activity

(P040) Radiosurgery for Primary Central Nervous System Lymphoma

(P041) Clinical Outcomes of Gamma Knife Stereotactic Radiosurgery (GK-SRS) for Painful Trigeminal Neuropathy (TNP)

(P042) Toxicity and Treatment Outcomes in Single vs Multifractionated Radiotherapy for Acoustic Neuromas

(P043) Central Neurocytoma: Impact of Resection Extent and Adjuvant Radiotherapy on Survival Outcomes

(P044) Treatment Outcomes of WHO Grade III Malignant Meningioma With and Without Postoperative Radiation Therapy

(P045) Multimodality Therapy With Intensity-Modulated Radiotherapy for Locally Advanced Esophageal Cancer

(P046) Prediction of Pathologic Complete Response After Neoadjuvant Chemoradiation Therapy for Rectal Cancer Using Radiographic Texture Analysis

(P047) The Role of Radiation Therapy Following Adjuvant Chemotherapy in Pancreatic Adenocarcinoma

(P048) Mutational Analysis by Next-Generation Sequencing in Patients With Pancreatic Adenocarcinoma

(P049) Increased Portal Venous Enhancement of Hepatocellular Carcinoma Following Transcatheter Arterial Chemoembolization

(P050) Yttrium-90 Radioembolization for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases in KRAS Wild-type and Mutant Patients

(P051) Intraductal Papillary Neoplasm of the Bile Duct: Prognostic Factors in SEER Outcomes of Benign and Malignant Cases

(P052) Human Papillomavirus in Esophageal Cancer: An Institutional Retrospective Analysis

(P053) Esophageal Cancer Pathologic Complete Response Rate After Neoadjuvant Chemoradiation: Is There a Difference Between Academic Centers vs Community Centers

(P054) Carbon Ion Therapy for Chinese Patients With Prostate Cancer: Primary Reports

(P055) Can High-Grade Prostate Cancer (Gleason 8-10) Be Cured With Definitive Local Therapy Without Testosterone Suppression? Five-Year Outcomes Employing Up-Front Prostatectomy in Patients With Clinically Localized, Nonmetastatic Disease

(P056) Ten-Year Outcomes of Patients With Gleason Score 9/10 Prostate Cancer Treated With Trimodality Therapy

(P057) A Population-Based Study of Men With Low-Volume, Low-Risk Prostate Cancer: Does African-American Race Predict for More Aggressive Disease?

(P058) The Long-Term Economic Value of Hypofractionated Prostate Radiation: A Cost Minimization Analysis of a Randomized Trial

(P059) Trends in the Utilization of Radiotherapy in the Management of Renal Cell Carcinoma

(P060) Impact of Major Psychiatric Disorders on Tolerance and Outcomes for Men With Prostate Cancer Undergoing Dose-Escalated Radiation Therapy

(P061) Anticoagulation Use and Improved Outcomes in a Predominantly African-American Population With High-Risk Prostate Cancer

(P062) Comparison of Stereotactic Body Radiotherapy (SBRT) and Conventional External Beam Radiotherapy (EBRT) in Renal Cell Carcinoma (RCC)

(P063) Can Some High-Risk Prostate Cancer Patients Be Treated With a Shorter Course of Androgen Deprivation Therapy (ADT)?

(P064) Outcomes After Adjuvant Radiation Therapy for Prostate Cancer at a Comprehensive Cancer Center

(P065) Lack of Variation in Pathologic Upgrading and Upstaging by Race Among Patients With Low-Risk Prostate Cancer

(P066) Dosimetric Analysis of Proton Therapy for Prostate Cancer: A Single Institutional Experience

(P067) The Role of Offline PET-CT Imaging in Evaluating the Particle Beam Range and Beam Stop for Prostate Cancer Treated With Heavy Ion Therapy

(P068) VMAT vs Eight-Field IMRT: Dosimetric Comparison of Pelvic Radiotherapy for High-Risk Prostate Cancer Patients in Terms of Bone Marrow Sparing

(P069) Gleason 7 Prostate Adenocarcinoma Treated With High- or Low-Dose-Rate Brachytherapy: Impact of External Beam Radiotherapy and/or Androgen Deprivation Therapy

(P070) High-Risk Prostate Adenocarcinoma Treated With Whole-Pelvis Radiotherapy HDR Brachytherapy Boost Results in Very High Disease-Specific Survival

(P071) Socioeconomic Disparities in Baseline Magnetic Resonance Imaging (MRI) Utilization and Imaging Characteristics for Prostate Cancer (PCa) Patients Undergoing Radiotherapy

(P072) Analysis of Composite EQD2 Dose Distribution in Radiotherapy for Cervical Cancer Using Central Shielding Technique

(P073) Optimal Epidural Analgesia During Interstitial Brachytherapy for Treatment of Gynecological Cancer

(P074) The Use of Stereotactic Body Radiotherapy in Lieu of Brachytherapy in Patients With Cervical or Endometrial Cancer

(P075) Management of Nodal Recurrences of Endometrial Cancer With IMRT

(P076) Postoperative Treatment Recommendations for Stage I Endometrial Cancer: A Survey of Society of Gynecologic Oncology Members

(P077) Defining the Pendulum Swing From Whole-Pelvic Radiation Therapy (WPRT) Alone to Vaginal Brachytherapy (VB) in the Adjuvant Setting for Endometrial Cancer: A SEER-Based Analysis From Years 2000-2011

(P078) Radiation Therapy in the Management of Carcinosarcoma of the Uterus

(P079) Retrospective Review of Chemoradiation in the Preoperative or Definitive Management of Locally Advanced Vulvar Cancer

(P080) Favorable Outcomes Using Radiation Therapy After Chemotherapy in the Management of Primary, Recurrent, and Metastatic Ovarian Cancer

(P081) SBRT Boost as a Substitute for Brachytherapy in the Definitive Treatment of Gynecologic Malignancies With Radiotherapy

(P082) Outcomes of Definitive Radiotherapy for T2N0 Squamous Cell Carcinoma of the Glottis: A Single-Institution Retrospective Study

(P083) Concurrent Chemotherapy + IMRT in Locally Advanced Squamous Cell Carcinoma of Head and Neck: What Is the Appropriate Chemotherapy?

(P084) Long-Term Functional and Oncologic Outcomes of Esthesioneuroblastoma

(P085) Oncologic and Functional Outcomes of Salivary Gland Tumors (SGTs) With Pathologically Proven Perineural Invasion (PNI)

(P086) Proton vs Photon/Electron-Based Therapy in the Treatment of Pediatric Salivary Gland Tumors: A Comparison of Dosimetric Data and Acute Toxicities

(P087) Proton Therapy Results in Low Rates of Acute GI Toxicity for Parotid Cancers

(P088) Nonadherence to NCCN Guidelines Negatively Impacts Survival in Early-Stage Squamous Cell Carcinoma of the Larynx

(P089) P16 as a Complementary Prognostic Marker for EBV-Positive Nasopharyngeal Carcinoma

(P090) Pediatric Metastatic Odontogenic Ghost Cell Carcinoma: A Multimodal Treatment Approach

(P091) Sarcopenia/Cachexia Is Associated With Reduced Survival and Locoregional Control in Head and Neck Cancer Patients Receiving Radiotherapy: Results From Quantitative Imaging Analysis of Lean Body Mass

(P092) Definitive Chemoradiotherapy or Radiotherapy for Unresectable, Very Locally Advanced, or Medically Inoperable Paranasal Sinus and Nasal Cavity Cancer

(P093) Cesium-131 Brachytherapy in High-Risk and Recurrent Head and Neck (HN) Cancers: Long-Term Results of a Pilot Study

(P094) Treatment Outcomes of Sinonasal Neuroendocrine Cancer: A Retrospective Review

(P095) *Abstract Withdrawn

(P096) Late Radiation-Associated Dysphagia (Late-RAD) With Lower Cranial Neuropathy After Oropharyngeal IMRT

(P097) Tumor Density, Size, and Histology in the Outcome of Stereotactic Body Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer: A Single-Institution Experience

(P098) Dosimetric Predictors of Pulmonary Toxicity in Patients With Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs

(P099) Influence of Surveillance PET/CT on Detection of Early Recurrence Following Definitive Radiation in Stage III Non–Small-Cell Lung Cancer

(P100) Intensity-Modulated Radiation Therapy After Extrapleural Pneumonectomy With and Without Chemotherapy for Malignant Pleural Mesothelioma: No Fatal Pulmonary Toxicity and Long-Term Survival

(P101) Does Maximum SUV From F-18 PET Scan Predict Outcomes for Early-Stage Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy (SBRT)?

(P102) Surgery Improves Survival in 14,228 Patients With Malignant Pleural Mesothelioma

(P103) A New Score Predicts Survival in Patients With Non–Small-Cell Lung Cancer

(P104) Esophagus- and Contralateral Lung–Sparing IMRT for Locally Advanced Lung Cancer in the Community Hospital Setting

(P105) Community-Based Early-Stage Treatment (BEST) Outcomes for NSCLC

(P106) Dosimetric Comparisons of Treatment by Different Radiotherapy Techniques for Stage III Non–Small-Cell Lung Cancer

(P107) Vero SBRT Treatment of Moving Lung Tumors

(P108) Stereotactic Body Radiation Therapy for the Treatment of Large (> 5 cm) Primary Non–Small-Cell Carcinoma

(P109) Standard Immunochemotherapy Plus Radiation vs Dose-Intense Chemotherapy With Rituximab in Stage I/II Primary Mediastinal Large B-Cell Lymphoma: A Single-Institution Experience

(P110) Hodgkin Lymphoma and Pregnancy: Treatment Patterns and Survival Outcomes of Women Treated With Modern Chemotherapy and Radiotherapy

(P111) Single-Isocenter Frameless Volumetric-Modulated Arc Radiosurgery for Multiple Intracranial Metastases

(P112) Spine Stereotactic Radiosurgery in the Treatment of Metastatic Pheochromocytoma: A Case Series

(P113) Posttreatment Sequelae for Long-Term Survivors of Brain Metastases

(P114) Radiotherapeutic Care Within the Veterans Health Administration of US Veterans With Metastatic Cancer to the Brain: Supportive Measures (Part 1 of 2 Reports)

(P115) The Experience of a Radiation Oncology Center in Gauging the Use of Single-Fraction Radiotherapy for Painful Bone Metastases

(P116) Pain and Radiographic Control After Stereotactic Radiosurgery for Spinal Metastases From Hepatocellular Carcinoma: A Comparison With Other Radioresistant Histologies

(P117) Outcomes, Patterns of Failures, and Toxicity for Patients Diagnosed With Pulmonary Metastases Treated With Stereotactic Body Ablative Radiotherapy (SABR)

(P118) Radiotherapeutic Care Within the Veterans Health Administration of US Veterans With Metastatic Cancer to the Brain: Part 2 Clinical Treatment Patterns

(P119) Electronic Brachytherapy Management of Atypical Fibroxanthoma: Report of Seven Cases

(P120) Pregnancy and Parenthood in Radiation Oncology, Views and Experiences Survey (PROVES): Results of a Blinded Prospective Trainee Parenting and Career Development Assessment

(P121) Image-Guided Radiation Therapy Utilization and Practice Patterns: Results From a National Survey of ASTRO Membership

(P122) Older African Americans’ Use of Religious Music to Cope With Cancer

(P123) Reducing Time From Patient CT Simulation (CT SIM) Appointment Time to Start of Actual CT Scan: Lean Thinking in the VA System

(P124) Dosimetric Comparison of Three-Dimensional Conformal Proton Radiotherapy and Intensity-Modulated Proton Therapy for Treatment of Pediatric Hodgkin Lymphoma

(P125) Glioblastoma Multiforme Outcome Comparison Between Pediatrics and Adults: Is There a Difference?

(P126) Long-Term Volumetric Follow-Up of Juvenile Pilocytic Astrocytomas Treated With Proton Beam Radiotherapy

(P127) Stereotactic Accelerated Partial Breast Irradiation (SAPBI) for Early-Stage Breast Cancer: Rationale, Feasibility, and Early Experience Using the CyberKnife Radiosurgery Delivery Platform

(P128) Statistically Significant Calibration Curve for Ir-192 HDR Source Using Multichannel Gafchromic Film Analysis

(P129) Bone Marrow Aspiration Under CT Guidance: Technique and Value

(P130) An Exploratory Pilot Study of Perfusion Patterns in Locoregionally Advanced Head and Neck Cancer Using a Novel Analysis Technique of Dynamic Contrast-Enhanced (DCE)-MRI

(P131) Improved Prostate Delineation in Prostate HDR Brachytherapy With TRUS-CT Deformable Registration Technology

(P132) Evaluation of the Chest Wall Skin Dose Associated With Bolus Application in Postmastectomy Radiation Therapy (PMRT) Using Nanodot OSLD

(P133) Spinal Cord Dose Comparison With and Without Contrast Density Correction on CT Myelogram Simulations for Patients Treated With Stereotactic Body or Conventional Radiotherapy

(P134) An Overview of the First One Hundred Patients Treated With a New Cutting-Edge, Frameless, Image-Guided, Stereotactic Radiosurgery System

(P135) Quantitative Assessment of Target Delineation Variability for Thymic Cancers: Agreement Evaluation of a Prospective Segmentation Challenge

(P136) Quantitative Measurement of Contrast Enhancement in Myxoid Liposarcomas: Response to Neoadjuvant Therapy With Volumetric and Pathologic Correlates

(P137) Seeing Is Believing: Concerns and Solutions in Implementing Magnetic Resonance Image Guided Radiation Therapy

(P138) Dosimetric Evaluation of Parotid Dose in Whole-Brain Radiation Plans Covering C1 vs C2

(P139) Clinical Outcomes and Patient-Reported Outcomes After Local Treatment for High-Risk, Localized Prostate Cancer

(P140) Clinical Predictors of Survival for Patients With Stage IV Cancer Referred to Radiation Oncology

(P141) Rectal Spacer Injection in Postprostatectomy Patients Undergoing High-Dose Salvage External Beam Radiation

(P142) Older Patients Derive Greater Benefit From Adjuvant and Neoadjuvant Radiotherapy in Diverse Solid Malignancies

(P143) Multisite Review of Twenty-Six Head and Neck Cancer Patients Who Have Developed Osteoradionecrosis: Location, Etiology, and Treatment

(P144) Radiation-Associated Toxicities in Obese Women With Endometrial Cancer: More Than Just BMI?

Related Videos
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Related Content